The English arm of the UK Bowel Cancer Screening Pilot study recently concluded its third round.
Dr Goodyear and colleagues from the United Kingdom assessed the impact of fecal occult blood test screening on the detection of symptomatic (non-screen-detected) cancers within the target age group.
|There was 23% reduction in the diagnosis of colorectal cancer over the 5 years|
|The British Journal of Surgery|
The team's secondary aim was to assess differences between screened and non-screened cohorts in Dukes' classification at diagnosis.
This population-based study utilized retrospective analysis of existing validated colorectal cancer data over 5 years, encompassing 2 rounds of screening.
The team found a 23% reduction in the diagnosis of colorectal cancer over the 5 years.
Presentations with symptomatic cancer reduced by 49%, with a proportionate 3-fold rise in the detection of screened asymptomatic malignancy.
Cancers were diagnosed at an earlier stage in the screened population, with significantly more Dukes' A tumors than in the non-screen-detected cohort.
The researchers noted that the odds ratio was 0.3 for Dukes' ‘D' cancers.
Fecal occult blood test screening resulted in a significant reduction in the number of symptomatic cancers detected within the target age group.
Dr Goodyear's team concluded, "Tumors detected by screening were diagnosed at an earlier pathological stage.